Pleural
Does hyperthermic povidone-iodine lavage increase the apoptotic rate of residual cancer cell in patients with malignant pleural mesothelioma?-a prospective pilot study
Translational Lung Cancer Research 2023 July 31 [Link] Andrea Bille, Hiral Jhala, Leanne Ashrafian, Leanne Allison, Matthew Russell, Roland Fleck, Daisuke Nonaka Abstract Background: Malignant pleural mesothelioma (MPM) is an incurable, late presenting primary cancer, conferring a survival of 8-14 months. Different intrapleural treatments have been tested as part of a multimodality approach to treat…
Read MoreCancer-Associated Fibroblasts Influence Survival in Pleural Mesothelioma: Digital Gene Expression Analysis and Supervised Machine Learning Model
International Journal of Molecular Science 2023 August 4 [Link] Sabrina Borchert, Alexander Mathilakathu, Alina Nath, Michael Wessolly, Elena Mairinger, Daniel Kreidt, Julia Steinborn, Robert F H Walter, Daniel C Christoph, Jens Kollmeier, Jeremias Wohlschlaeger, Thomas Mairinger, Luka Brcic, Fabian D Mairinger Abstract The exact mechanism of desmoplastic stromal reaction (DSR) formation is still unclear. The…
Read MoreCost Effectiveness and Budget Impact of Nivolumab Plus Ipilimumab Versus Platinum Plus Pemetrexed (with and Without Bevacizumab) in Patients with Unresectable Malignant Pleural Mesothelioma in Switzerland
Pharmacoeconomics 2023 August 12 [Link] Michaela Carla Barbier, Alicia Fengler, Esther Pardo, Arjun Bhadhuri, Niklaus Meier, Oliver Gautschi Abstract Background: Malignant pleural mesotheliomas (MPMs) are aggressive and often unresectable. In the past, chemotherapy was the standard for palliative treatment. However, immunotherapy with nivolumab+ipilimumab has recently received marketing approval. Objectives: This study evaluated the cost effectiveness…
Read MoreGermline Variants Incidentally Detected via Tumor-Only Genomic Profiling of Patients With Mesothelioma
JAMA Network Open 2023 August 1 [Link] Owen D Mitchell, Katie Gilliam, Daniela Del Gaudio, Kelsey E McNeely, Shaili Smith, Maria Acevedo, Meghana Gaduraju, Rachel Hodge, Aubrianna S S Ramsland, Jeremy Segal, Soma Das, Feighanne Hathaway, Darren S Bryan, Sanjukta Tawde, Shelly Galasinski, Peng Wang, Melissa Y Tjota, Aliya N Husain, Samuel G Armato 3rd,…
Read MoreHyperthermic intrathoracic extracorporeal chemotherapy for secondary malignant pleural disease
Journal of Surgical Oncology 2023 September [Link] Daniel L Miller, Christopher S Parks, Brittany Ange, Ioana R Bonta, Patricia T Rich Abstract Objectives: Pleural metastasis has extremely poor prognosis. Resection of pleural implants with infusion of intrathoracic hyperthermic chemotherapy may offer a survival advantage in selected patients. We evaluated the safety and efficacy of hyperthermic…
Read MoreLongitudinal monitoring of response to chemotherapy in patients with malignant pleural mesothelioma by biomarkers
Cancer Biomarkers 2023 [Link] Filiz Bogar, Guntulu Ak, Selma Metintas, Adnan Ayhanci, Muzaffer Metintas Abstract Background: The aim of the study was to longitudinally investigate the serum levels of mesothelin, sestrin1, hyaluronan synthase 2 (HAS2), midkine, and high mobility group box 1 (HMGB1) before and after chemotherapy and at the time of relapse in malignant…
Read MoreOmics Overview of the SPARC Gene in Mesothelioma
Biomolecules 2023 July 11 [Link] Licun Wu, Marc de Perrot Abstract The SPARC gene plays multiple roles in extracellular matrix synthesis and cell shaping, associated with tumor cell migration, invasion, and metastasis. The SPARC gene is also involved in the epithelial-mesenchymal transition (EMT) process, which is a critical phenomenon leading to a more aggressive cancer…
Read MoreExpression of TILs and Patterns of Gene Expression from Paired Samples of Malignant Pleural Mesothelioma (MPM) Patients
Cancers 2023 July 14 [Link] Susana Cedres, Garazi Serna, Alberto Gonzalez-Medina, Augusto Valdivia, Juan David Assaf-Pastrana, Patricia Iranzo, Ana Callejo, Nuria Pardo, Alejandro Navarro, Alex Martinez-Marti, Ilaria Priano, Roberta Fasani, Xavier Guardia, Javier Gonzalo, Caterina Carbonell, Joan Frigola, Ramon Amat, Victor Navarro, Rodrigo Dienstmann, Ana Vivancos, Paolo Nuciforo, Enriqueta Felip Abstract MPM is an aggressive…
Read MorePredicting survival for patients with mesothelioma: development of the PLACE prognostic model
BMC Cancer 2023 July 26 [Link] Yuan Zhang, Nan Li, Ran Li, Yumei Gu, Xiaofang Liu, Shu Zhang Abstract Introduction: The overall survival of patients with mesothelioma is poor and heterogeneous. At present, the prediction model for Chinese patients needs to be improved. We sought to investigate predictors of survival in malignant pleural mesothelioma and…
Read MorePleural Mesothelioma in the Era of Immunotherapy
Clinical Medicine Insights Oncology 2023 July 20 [Link] Mathieu Chevallier, Floryane Kim, Alex Friedlaender, Alfredo Addeo Abstract Over the course of the last decade, immunotherapy has revolutionised the management of a great number of cancer types. The treatment of pleural mesothelioma, a rare and highly aggressive cancer, is also being transformed by immunotherapy. The recent…
Read More